Arno Frigg1,2, Ursula Germann3,4, Martin Huber4, Monika Horisberger3. 1. Orthopedic Department, University of Basel, Spitalstrasse 21, 4031, Basel, Switzerland. mail@arnofrigg.com. 2. Foot and Ankle Surgery Zürich, Bahnhofstrasse 56, 8001, Zürich, Switzerland. mail@arnofrigg.com. 3. Orthopedic Department, University of Basel, Spitalstrasse 21, 4031, Basel, Switzerland. 4. Foot and Ankle Surgery Bern, Schänzlistrasse 33, 3013, Bern, Switzerland.
Abstract
PURPOSE: The purpose of this study was to evaluate survival and clinical outcome of the Scandinavian total ankle replacement (STAR) prosthesis after a minimum of ten years up to a maximum of 19 years. METHODS: Fifty STAR prostheses in 46 patients with end stage ankle osteoarthritis operated between 1996 and 2006 by the same surgeon (MH) were included. Minimal follow-up was ten years (median 14.6 years, 95% confidence interval [CI] 12.9-16.4). Clinical (Kofoed score) and radiological assessments were taken before the operation and at one, ten (+2), and 16 (±3) years after implantation. The primary endpoint was defined as exchange of the whole prosthesis or conversion to arthrodesis (def. 1), exchange of at least one metallic component (def. 2), or exchange of any component including the inlay (due to breakage or wear) (def. 3). Survival was estimated according to Kaplan-Meier. Further reoperations related to STAR were also recorded. RESULTS: The ten year survival rate was (def. 1) 94% (CI 82-98%), (def. 2) 90% (CI, 77-96%), and (def. 3) 78% (CI 64-87%). The 19-year survival rate was (def. 1) 91% (CI 78-97%), (def. 2) 75% (CI 53-88%), and (def. 3) 55% (CI 34-71%). Considering any re-operations related to STAR, 52% (26/50) of prostheses were affected by re-operations. Mean pre-operative Kofoed score was 49, which improved to 84 after one year (n = 50), to 90 after ten years (n = 46), and to 89 after 16 years (n = 28). CONCLUSIONS: The survival rate for def. 1 and 2 was high. However, re-operations occurred in 52% of all STAR prosthesis. STUDY DESIGN: Retrospective cohort study, evidence Level 4.
PURPOSE: The purpose of this study was to evaluate survival and clinical outcome of the Scandinavian total ankle replacement (STAR) prosthesis after a minimum of ten years up to a maximum of 19 years. METHODS: Fifty STAR prostheses in 46 patients with end stage ankle osteoarthritis operated between 1996 and 2006 by the same surgeon (MH) were included. Minimal follow-up was ten years (median 14.6 years, 95% confidence interval [CI] 12.9-16.4). Clinical (Kofoed score) and radiological assessments were taken before the operation and at one, ten (+2), and 16 (±3) years after implantation. The primary endpoint was defined as exchange of the whole prosthesis or conversion to arthrodesis (def. 1), exchange of at least one metallic component (def. 2), or exchange of any component including the inlay (due to breakage or wear) (def. 3). Survival was estimated according to Kaplan-Meier. Further reoperations related to STAR were also recorded. RESULTS: The ten year survival rate was (def. 1) 94% (CI 82-98%), (def. 2) 90% (CI, 77-96%), and (def. 3) 78% (CI 64-87%). The 19-year survival rate was (def. 1) 91% (CI 78-97%), (def. 2) 75% (CI 53-88%), and (def. 3) 55% (CI 34-71%). Considering any re-operations related to STAR, 52% (26/50) of prostheses were affected by re-operations. Mean pre-operative Kofoed score was 49, which improved to 84 after one year (n = 50), to 90 after ten years (n = 46), and to 89 after 16 years (n = 28). CONCLUSIONS: The survival rate for def. 1 and 2 was high. However, re-operations occurred in 52% of all STAR prosthesis. STUDY DESIGN: Retrospective cohort study, evidence Level 4.
Entities:
Keywords:
Complications; Re-operations; Star; Survival; Total ankle replacement
Authors: Fabian G Krause; Markus Windolf; Biraj Bora; Murray J Penner; Kevin J Wing; Alastair S E Younger Journal: J Bone Joint Surg Am Date: 2011-04-15 Impact factor: 5.284
Authors: Samuel Brunner; Alexej Barg; Markus Knupp; Lukas Zwicky; Ashley L Kapron; Victor Valderrabano; Beat Hintermann Journal: J Bone Joint Surg Am Date: 2013-04-17 Impact factor: 5.284
Authors: Jakub Wąsik; Tomasz Stołtny; Jarosław Pasek; Karol Szyluk; Michał Pyda; Alina Ostałowska; Sławomir Kasperczyk; Bogdan Koczy Journal: Med Sci Monit Date: 2019-09-10